Gastric Cancer

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

http://dx.doi.org/10.1007/s10120-014-0391-x

Post author By Poole C D, Connolly M P, Chang J and Currie C J
Post date 24 June 2014

Poole C D, Connolly M P, Chang J, Currie C J. 24 Jun 2014

Poole C D

Connolly M P

Chang J

Currie C J

Transforming real-world data into transparent, reliable, and reliable real-world evidence

44 (0) 2920 782856

enquiries@humandatasciences.com

24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone® is a Trusted Research Environment (TRE)

Quick Links

Transforming real-world data into transparent, reliable, and replicable real-world evidence

44 (0) 2920 782856

instantRWE@humandatasciences.com

The Global Pharma Research Centre,
24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone^® is a Trusted Research Environment (TRE)

Web Design – Create Summit

Site by Create Summit